Co-Diagnostics (CODX) saw its stock price surge dramatically in heavy Nasdaq trading on Tuesday, climbing 78% to $9.03 after the molecular diagnostics company announced progress in developing a polymerase chain reaction (PCR) test for the Bundibugyo strain of Ebola. The test is being developed in response to a rapidly spreading outbreak in central Africa, with over 46.5 million shares traded, a massive volume for a company with a market capitalization of approximately $20.3 million.
The Salt Lake City-based company said it is working through its Indian joint venture, CoSara Diagnostics, with Ambalal Sarabhai Enterprises, to advance a PCR assay strategy for the Bundibugyo strain. PCR tests detect genetic material from pathogens, providing laboratories with a method to confirm infections. The company noted that the test is still under development and has not yet received regulatory approval for sale.
The market's reaction was fueled by the escalating health crisis. On Monday, World Health Organization Director-General Tedros Adhanom Ghebreyesus warned that the outbreak was spreading rapidly, with over 900 suspected cases and 220 suspected deaths. He stated that responders were "playing catch-up" as the epidemic was "outpacing us," and noted that there are no approved vaccines or therapeutics for the Bundibugyo virus. The European Centre for Disease Prevention and Control reported 105 confirmed cases and 10 confirmed deaths in the Democratic Republic of Congo, along with 906 suspected cases and 223 suspected deaths, while Uganda had seven confirmed cases, including one death.
Chief Executive Dwight Egan expressed confidence that Co-Diagnostics could collaborate with CoSara to deliver "accurate, reliable PCR diagnostics" in response to emerging health crises. The company is evaluating both Bundibugyo-specific and pan-Ebola assay configurations, the latter designed to detect multiple ebolavirus species. However, the company cautioned that its Co-Dx PCR platform and related tests remain subject to regulatory review and are not yet for sale.
Despite the rally, a recent filing reveals significant financial challenges. A May 21 filing showed that Co-Diagnostics entered a $3.0 million private placement, selling common stock, pre-funded warrants, and warrants to selected investors. The warrants carry an exercise price of $1.571 per share and are exercisable immediately. This financing is critical as the company's balance sheet is thin. Co-Diagnostics reported first-quarter product revenue of $145,954, a net loss of $9.14 million, and cash and equivalents of $8.23 million as of March 31. Operating cash use was $7.85 million in the quarter.
Adding to the concern, the company's May 10-Q filing stated that management had concluded there was "substantial doubt" about its ability to continue as a going concern for 12 months after the financial statements were issued. This means the company may need additional capital or improved operating results to meet its obligations over the next year.
Competition in the diagnostics space is fierce. Co-Diagnostics faces larger, well-resourced players such as Roche Diagnostics, Cepheid, and Abbott Laboratories, which have broader customer bases and deeper financial resources. The company's assay strategy is still in the development stage, regulatory clearance is uncertain, and outbreak demand could shift if public health teams contain the virus or if larger diagnostics suppliers move faster.
For now, traders are treating Co-Diagnostics as a small-cap outbreak-response play rather than an earnings story. The key factors to watch include public health case counts, any regulatory updates on the assay, and whether the company can convert its scientific progress into orders without needing to raise additional capital on unfavorable terms. The recent stock surge reflects market optimism, but the underlying financial risks remain significant.
